Innate Pharma S.A.
Innate Pharma S.A. (IPHA) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · IPHA · as of Jun 8, 2026
Key Statistics
Explore Innate Pharma S.A. Data
ipha stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 6 · Buy rate: 66.7%
The IPHA analyst consensus is Buy, based on ratings from 6 Wall Street analysts over the past 3 months. The average 12-month price target is $3.50, representing +98.86% upside from the current price of $1.76.
Competitors & Peers
ipha competitorsIPHA
APLT
CGEN
CRBP
CRDF
CYBNStock Performance
Full HistoryAbout Innate Pharma S.A.
Innate Pharma S.A. a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's produ…
what is innate pharma s.a. · ipha stock overview · innate pharma s.a. company profile · who is innate pharma s.a. ceo · ipha NASDAQ · innate pharma s.a. headquarters · innate pharma s.a. business segments
About Stock Overview & Key Data
Innate Pharma S.A. (IPHA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Oct 17, 2019. As of the latest trading session, IPHA stock price is $1.76, with a market capitalization of $165.3M. The stock has returned -15.38% over the past 12 months and +0.57% year-to-date.
According to 6 Wall Street analysts, the consensus rating for Innate Pharma S.A. stock is Buy, with an average 12-month price target of $3.50. In fiscal year 2025, Innate Pharma S.A. reported revenue of $2.8M and net income of -$49.2M. For detailed data — including Innate Pharma S.A. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Innate Pharma S.A. (IPHA) stock price is $1.76. The stock is traded on NASDAQ under the ticker symbol IPHA. The 52-week range is $1.17 – $2.63.